title: [Efficacy and safety of cefditoren pivoxil in treatment of respiratory infections, a clinical study].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of cefditoren pivoxil in treatment of respiratory infections.
  
  
  METHODS
  199 cases of respiratory infection confirmed by etiological and clinical examinations were treated with cefditoren pivoxil tablets taken orally. Therapeutic evaluation was conducted among 196 cases and safety evaluation was conducted among 199 cases.
  
  
  RESULTS
  The total effective rate was 94.9%, and the causative bacteria -elimination rate was 96.7%. Clinical adverse events, including moderate diarrhea, mild nausea and vomiting, and stomach discomfort, were seen in 9 cases with an incidence rate of 4.5%. Laboratory adverse events, including increase of with an incidence rate of 3.5%.
  
  
  CONCLUSIONS
  Cefditoren pivoxil is effective and safe in treatment of mild and moderate respiratory infections. The resistance rate to cefditoren pivoxil of pathogens of respiratory infections and the efficacy of cefditoren pivoxil show no difference from those tested 7 years ago.
authors.affiliation: Department of Antibiotics, Institute of Clinical Pharmacology, Peking University, Beijing 100083, China.
authors.forename: Jia-Tai
authors.initials: JT
authors.lastname: Li
authors.forename: Lei
authors.initials: L
authors.lastname: Gao
authors.forename: Feng
authors.initials: F
authors.lastname: Xue
authors.forename: Feng-Lan
authors.initials: FL
authors.lastname: Hao
authors.forename: Qi
authors.initials: Q
authors.lastname: Wang
authors.forename: Bai-Qiang
authors.initials: BQ
authors.lastname: Cai
authors.forename: Chun-Lan
authors.initials: CL
authors.lastname: Gan
authors.forename: You-Ning
authors.initials: YN
authors.lastname: Liu
authors.forename: Bing-Xiang
authors.initials: BX
authors.lastname: Yu
authors.forename: Li-Xian
authors.initials: LX
authors.lastname: He
authors.forename: Bi-Jie
authors.initials: BJ
authors.lastname: Hu
authors.forename: Xue-Hua
authors.initials: XH
authors.lastname: Chen
authors.forename: Jing-Chuan
authors.initials: JC
authors.lastname: Zheng
authors.forename: Yun-Song
authors.initials: YS
authors.lastname: Yu
authors.forename: Fang-Fang
authors.initials: FF
authors.lastname: Lu
authors.forename: De-Rong
authors.initials: DR
authors.lastname: Liang
authors.forename: Yong-Ning
authors.initials: YN
authors.lastname: Cai
authors.forename: Jian
authors.initials: J
authors.lastname: Kang
authors.forename: Ling-Fei
authors.initials: LF
authors.lastname: Kong
authors.forename: Zheng-Lun
authors.initials: ZL
authors.lastname: Xiao
authors.forename: Jin-Ping
authors.initials: JP
authors.lastname: Zheng
authors.forename: Jie
authors.initials: J
authors.lastname: Liu
authors.forename: Wei-Xing
authors.initials: WX
authors.lastname: Yang
authors.forename: Jing
authors.initials: J
authors.lastname: Zhou
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002511:Cephalosporins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D011358:Product Surveillance, Postmarketing; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C057710:cefditoren pivoxil